

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger

Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey\* Heidi L. Kraus Edward W. Yee Albert L. Ferro\* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Albert J. Fasulo II\* Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono

Virgil Lee Beaston\*
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingler
Rae Lynn Prengaman
Jane Shershenovich\*
Lawrence J. Carroll\*
George S. Bardmesser
Daniel A. Klein\*
Rodney G. Maze
Jason D. Eisenberg
Michael A. Specht\*
Andrea J. Kamage
Tracy L. Muller\*

Jon E. Wright\* LuAnne M. Yuricek\* Registered Patent Agents • Karen R. Markowicz

Karen R. Markowicz Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Angelique G. Uy Boris A. Matvenko Mary B. Tung Katrina Y. Pei Bryan L. Skelton Robert A. Schwartzman John J. Figueroa Timothy A. Doyle Jennifer R. Mahalingappa Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford W. Brian Edge

Senior Counsel Samuel L. Fox Kenneth C. Bass III Lisa A. Dunner

\*Admitted only in Maryland

\*Admitted only in Virginia

\*Admitted only in Texas

\*Practice Limited to
Federal Agencies

January 16, 2003

WRITER'S DIRECT NUMBER:
(202) 789-5519
INTERNET ADDRESS:
MTRAN@SKGF.COM

Art Unit 1636

Commissioner for Patents Washington, D.C. 20231

Re: U.S. Utility Patent Application

Appl. No. 09/907,900; Filed: July 19, 2001

For: Recombinational Cloning Using Nucleic Acids Having Recombination Sites

Inventors: Hartley et al.

Our Ref: 0942.285000D/BJD/MTT

RECEIVED

JAN 177 2003

TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Supplemental Preliminary Amendment and Reply to Restriction Requirement; and
- 2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents January 16, 2003 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mau T. Tran

Registration No. P-53,699

Wan V. Tuo

BJD/MTT/acr Enclosures

SKGF\_DC1:91732.1



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#91B PP 1-1803

In re application of:

Hartley et al.

Appl. No. 09/907,900

Filed: July 19, 2001

For: Recombinational Cloning Using

Nucleic Acids Having Recombination Sites

Confirmation No. 1831

Art Unit: 1636

Examiner: Sandals, W.O.

Atty. Docket: 0942.285000D/BJD/MTT

Supplemental Preliminary Amendment and Reply To Restriction Requirement RECEIVED

Commissioner for Patents Washington, D.C. 20231

JAN 1 7 2003

TECH CENTER 1600/2900

Sir:

In reply to the Office Action dated **December 17, 2002** (Paper No. 8), Applicants submit the following amendments and remarks. This Supplemental Preliminary Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks. See 37 C.F.R. § 1.121 and MPEP § 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

Please amend the application as follows:

## In the Claims:

Please cancel claim 1, without prejudice to or disclaimer of the subject matter contained therein.